Matthew Newman

6PUBLICATIONS
7CO-AUTHORS
Nanotoxicology, health and safetyCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Regenerative medicine (incl. stem cells)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 21, 2024
Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients.

Daniel Skoloda, Matthew Newman, Haval Norman

|Jun 17, 2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.

Kyle Zacholski, Bryan Hambley, Erin Hickey

|Feb 17, 2021
Recognizing the potential for copper-related toxicities from liposomal daunorubicin--cytarabine.

Matthew J Newman

|Nov 20, 2020
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.

Valerie Relias, Ali McBride, Matthew J Newman

|May 29, 2019
Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.

Carmen F Nobre, Matthew J Newman, Anne DeLisa

|Mar 05, 2016
Azacitidine-Induced Pericarditis: A Case Series.

Matthew Newman, Midhun Malla, Ivana Gojo

Pageof 1